ISA Pharmaceuticals selects product candidate for clinical trial with first in class COVID-19 immunotherapy

First Patient Treated in Phase II Combination Trial of ISA Pharmaceuticals’ Lead Immunotherapy ISA101b with Keytruda®

ISA106 – SLP therapeutic for COVID-19